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Fox proteins superfamily
Forkhead box (Fox) proteins are a superfamily of 
transcriptional regulators, which control a wide range 
of biological processes, therefore, a disturbance of Fox 
activity can alter cell development, initiate tumorogenesis 
and cancer metastasis. There are several Fox subfamilies 
such as FoxN, FoxO, FoxM, FoxP, FoxC and FoxA that 
are involved in tumor development and progression. Fox 
proteins can be considered as direct and indirect targets for 
therapeutic intervention, as well as biomarkers to predict 
and monitor treatment responses (1).
The regulation of Fox proteins activity is an important 
process that can be controlled by multiple post-translational 
modifications as phosphorylation, acetylation and 
ubiquitylation. These modifications control the site and 
activity of fox proteins within the cells. Fox proteins in the 
nucleus are active and act as transcriptional regulators; while 
Fox proteins in the cytoplasm are inactive and subjected to 
proteosomal degradation. The alternation in Fox proteins 
site whether in the nucleus or the cytoplasm is mediated 
through their import and export from the nucleus. This is 
regulated through a complex sequence of phosphorylation 
and acetylation (1).
Functions of Fox proteins
FoxP3 plays a regulatory role in T cell differentiation in 
addition to cancer initiation and progression (2). It has 
been reported that FoxP3 expression is down regulated in 
multiple tumors as breast, ovarian and prostatic carcinoma, 
which indicates that FoxP3  is an important tumor 
suppressor gene. In prostate and breast cancer cells, FoxP3 
inhibits the expression of SATB1, MYC, HER2 and Skp2 
oncogenes and stimulates the expression of P21 and LATS2 
tumor suppressor genes so act to inhibit tumor growth and 
proliferation (3).
Foxp3 recruits other anti-tumor enzymes that inhibit 
CD39 and CD8. In melanoma and ovarian cancer patients, 
CD39 is over expressed which protects tumor cells by 
allowing them to create their “escape phase” in which 
tumor cells divide rapidly and cannot be detected clinically. 
Tumor cells create immunosuppressive microenvironment 
and become independent of the extracellular matrix. As a 
consequence, the tumor cells completely evade the immune 
system and metastasize (4). 
Nuclear Foxp3 regulates NF-κB and NFAT, transcription 
factors which regulate cytokine production, transcription 
of DNA, cell survival and apoptosis. P60 inhibits Foxp3’s 
translocation to the nucleus thus inhibiting the ability of 
the cells to induce apoptosis, allowing the cancerous cell 
to survive and reproduce (4). In addition, FOXN3 acts as 
a tumor suppressor, inhibiting cell proliferation by down 
regulating E2F5 (5).
Metastasis is a highly organized process; it is directed by 
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receptors for specific chemotactic cytokines, or chemokines. 
The most common sites for metastatic spread of breast 
cancer cells include the lung, liver, brain and bones. 
These sites are known to express the chemokine CXCL12 
that stimulates the receptor CXCR4 which is frequently 
expressed by breast cancer cells. The interaction between 
CXCL12 and CXCR4 increases HER2 level (3). 
Normal healthy breast epithelium expresses low levels 
of HER2 as FOXP3 directly binds and represses the 
expression of ErbB2. ErbB2 increases the expression of 
HER2. In case of cancer breast, FOXP3 loses the capability 
to repress ErbB2, thus the levels of ErbB2 transcripts 
increases, resulting in a greater expression of cell surface 
HER2 (HER2 is a cell surface molecule and is an important 
prognostic marker which is overexpressed in breast cancer 
and correlates to a more aggressive phenotype). The 
increased expression of HER2 results in the increased 
expression of CXCR4 which allows more of the CXCR4 
ligand and CXCL12 to bind and increase the expression of 
HER2, thereby creating a feedback loop (3).
FOXP3 is a tumor suppressor gene, it promotes cell 
adhesion through repression of CD44 protein expressions, 
leading to reduction of metastatic invasion of breast 
carcinoma cells (6). 
CD44 promotes epithelial mesenchymal transition (EMT) 
in many cancer types by up regulating mesenchymal markers 
and down regulating epithelial markers. CD44 inhibits the 
formation of the membrane-associated E-cadherin-β-catenin 
complex, which resulted in the nuclear translocation of 
β-catenin and activation of transcription of genes related to 
cell invasion and migration (7). 
FOXO is also a tumor suppressor gene that inhibits 
tumorigenesis through senescence induction. FOXO acts to 
prevent the establishment of damaged cells; such cells are 
continuously exposed to stress by induction of apoptosis or 
repair mechanisms (Figure 1). Damaged cells can potentially 
progress to tumor cells. Many tumors provide a protective 
mechanism to counter act the tumor suppressor effect of 
FOXO. These tumors exhibit constitutive PI3K-protein 
kinase B (PKB) signaling. Enhanced constitutive PI3K-PKB 
signaling inhibits FOXO signaling and inhibits apoptosis, 
thus favoring damaged cell establishment (8).
On the other side, tumor progression by itself generates 
a stressful condition caused by rapid proliferation and 
decrease oxygen and nutrient supply to these large numbers 
of cells. In this condition, the oxidative stress can overcome 
the inhibitory effect of PI3K-PKB caused by tumor cells 
on FOXO. This means that the tumor cells can use FOXO 
for its own to withstand these adverse conditions. This can 
occur by interaction of FOXO and β-catenin, encouraging 
metastasis to escape from these local adverse conditions. 
So FOXO can act both as tumor suppressors and as 
homeostatic regulators in tumor cells (8).
Long non coding RNA NEAT1
Nuclear enriched abundant transcript 1 (NEAT1), is a long 
non-coding RNA (lncRNA), involved in the development 
of many cancer types and it is found to be unregulated in 
breast cancer cell lines and promotes its growth by acting 
on miR-101 (9).
NEAT1 like other lncRNA cannot be translated to 
protein, but act to form a subnuclear particle called 
paraspeckles. Although the function of this particle is still 
unknown, it seems to play a protective mechanism for cancer 
cells. When cancer cells are stressed or have DNA damage, 
P53 up regulates NEAT expression leading to formation of 
these paraspeckles to allow repair mechanisms. Thus NEAT 
and paraspeckles are required for cancer cells survival, as the 
normal cells don’t rely on this mechanism. This is confirmed 
by the fact that mice lacking NEAT1 are protected from 
skin cancer development, moreover loss of NEAT1 leads 
to increased chemosensitivity and cell death. NEAT1 helps 
cancer cells to grow opportunistically and survive standard 
chemotherapeutics. Therefore drugs targeting NEAT1 are 
promising agents in cancer therapy (10).
SIN3A is a repressor transcription factor
SIN3 is a large protein having an important role in 
regulation of transcription. It has multiple protein–protein 
Figure 1 The effect of stress on FOXO pathway.
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interaction domains which act as a scaffold to help in 
assembly of corepressor complex. The mammalian SIN3A 
corepressor complex contains 7–10 tightly associated 
polypeptides, including HDAC1, HDAC2, RbAp46, 
RbAp48, RBP1, SAP30, and p33ING1b, which associate 
with SIN3 and act as a component of a “core” SIN3 
corepressor complex (11). Sin3A can be considered as a 
negative regulator of multiple cancer-associated factors as 
p53, Rb, E2F and Myc (12). 
Sin3A interact with DNA-binding or adaptor proteins 
to target the promoter of the considered gene, as it lacks 
intrinsic DNA binding domain. Examples for these proteins 
are: Mad, NRSF, p53 and MeCP2 (13). 
Estrogen receptor alpha (ERα) can both activate and 
repress gene transcription, depending on the ligand, so it 
can be considered as ligand activated transcription factor.  
Estrogen can inhibit ERα gene transcription by recruitment 
of Sin3A to target promoters. In case of estrogen treatment, 
ERα is recruited to ERα gene (ESR1) on two sites, one at 
the proximal (A) promoter and the other at distal (ENH1). 
Coactivator proteins, AIB1 and p300, are recruited at both 
ERα-binding sites. Whereas Sin3A repressor recruitment, 
histone modifications and loss of RNA polymerase II, 
occurred only at the proximal (A) promoter. The repression 
effect of ERα caused by Sin3A at the proximal (A) promoter 
of ESR1 overcomes activating factors in distal and proximal 
regions (14). This can be approved as this estrogen induced 
inhibition on ESR1is eliminated when the expression of 
SIN3A is reduced by RNA interference.
Wanjin et al., 2017 reported that FOXN3 can be 
considered as a transcription repressor. It interacts in 
human cells with the SIN3A complex. They found that only 
in ER+ breast cancer cells with absence of RNase, FOXN3 
with the SIN3A complex interaction is detected. Depending 
on the previous studies which revealed that protein-protein 
interactions requires several lncRNAs (15), they identified, 
by iRIP-Seq, that lncRNA, NEAT1 is required for the 
interaction, and proposed that FOXN3 recruits SIN3A 
complex by the aid of NEAT1 to the chromatin to inhibit 
the transcription of several genes, suggesting that NEAT1 
is important regulator at the epigenetic level.
In addition to the known effect of SIN3A in transcription 
inhibition, the SIN3A complex has a protein component 
SAP18; it is an RNA-binding protein that can interact 
with NEAT1. NEAT1-SIN3A complex can be recruited 
by multiple transcription repressors other than FOXN3 in 
other cell types, which means that NEAT1 is a facultative 
component of the SIN3A complex. 
FOXN3-NEAT1-SIN3A complex and breast cancer 
Depending on a previous finding that NEAT1 is an ERα 
target in prostate cancer and in breast carcinoma with ER+ 
cells where NEAT1 is induced by estrogen (16), Wanjin et al., 
2017 reported that by ChIP-Seq studies and by analysis of 
NEAT1 CHART-Seq results, FOXN3- NEAT1-SIN3A 
complex inhibit the transcription of GATA3 and TJP1, and 
both FOXN3 and NEAT1 are involved in malignancies of 
several tissues through promotion of EMT and invasive 
metastasis of breast cancer cells (17).
There is a feedback loop interaction between ERα and 
FOXN3-NEAT1-SIN3A complex. When ERα activates 
NEAT1, it interacts with SIN3A which then complexed 
with FOXN3 and form FOXN3-NEAT1-SIN3A complex 
(Figure 2) (17). 
ERα is required for ERα+ breast carcinoma cells growth 
and multiplication. Since cells growth and differentiation 
are different and uncoupled process (18), in mammary 
epithelial cells when growth process is favored, ERα 
induces NEAT1 to assemble in a complex with SIN3A and 
FOXN3 and inhibits the transcription of GATA3 and TJP1 
genes responsible for maintenance and differentiation. On 
the other hand when the cell differentiation is favored, 
Figure 2 The interaction between NEAT1, FOXN3 and SIN3A.
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the growth signal initiated by ERα is attenuated allowing 
the expression of GATA3 and TJP1. The balance in this 
regulatory mechanism is required for normal development 
of mammary epithelial cells. The disturbance in this balance 
leads to breast cancer development and metastasis (17).
GATA3 and TJP1 genes and cancer cells 
metastasis
GATA3 is a transcription factor restricted to mammary 
epithelium where it is highly expressed. It maintains luminal 
epithelial cell differentiation (19).
GATA3 is responsible for cell differentiation and 
inhibition of cancer cell metastasis, so when its expression is 
lost in breast carcinoma, it indicates bad prognosis. GATA3 
produces its effect by inducing microRNA-29b (miR-29b) 
expression. miR-29b can inhibit metastasis by acting on 
VEGFA, ANGPTL4, PDGF, LOX and MMP9, ITGA6, 
ITGB1 and TGFB. These factors act as pro-metastatic 
regulators by acting on angiogenesis, collagen remodeling 
and proteolysis, thus miR-29b can affect cell differentiation 
and epithelial plasticity. Even in GATA3-expressing cells, 
loss of miR-29b, increases metastasis and promotes a 
mesenchymal phenotype. GATA3 can also inhibit cancer 
metastasis by increasing the expression of E-cadherin, 
increasing cell adhesion. GATA3 and its miR-29b seem to 
be a new target in cancer therapy (20). 
Tight junction protein-1 is a peripheral membrane 
protein of 220-kD that is encoded by the TJP1 gene. It 
acts as a scaffold protein to anchor the Tight Junction (TJ) 
strand proteins, which are fibril-like structures within the 
cell membrane lipid bilayer, to the actin cytoskeleton (21).
TJPs have an important role in the normal epithelial 
function. TJPs establish and maintain epithelial cell polarity 
by acting as a diffusion barrier to proteins and lipids 
movement through the cell membrane and monitoring 
multiple processes such as cell polarity, morphogenesis, cell 
differentiation and proliferation (22). 
The impairment of tight junction proteins functions 
are observed in many cancers. This impairment leads to 
increase in entry of nutrients and signaling peptides and 
down-regulation of cell-cell adhesion molecules leading to 
increased motility and metastasis of cancer cells (23).
Fox proteins and cancer therapy
Since Fox superfamily proteins have important roles 
in different biological processes, any disturbance in its 
signaling will lead to development of a wide range of 
disease, even cancer development and metastasis. Fox 
proteins can act as oncogenes or tumor suppressor genes 
through their interaction with regulatory factors as p53 
and ER. Thus fox proteins can be considered as a target 
in breast carcinoma therapy in combination with other 
treatment strategies. 
This combination reduces the toxic side effects of 
these strategies on normal cells. For example, a chemo-
resistant breast cancer cell lines when sensitized to activates 
FOXO3A, it becomes more responsive to chemotherapy (1). 
ER alpha is a prognostic factor for breast carcinoma 
invasiveness, as ER positive cancer is more responsive 
to endocrinal treatment than ER negative. Also ER 
alpha expression is controlled by FOXA1, FOXO3A and 
FOXM1 (24).
Therapies that target factors controlling Fox expression 
or its post translational regulation can modify the chemo 
sensitivity of breast cancer cells. HDACs inhibition 
modulates FOXO3A activity in cancer cells and induces 
apoptosis when DNA damage occurs rather than DNA 
repair and cell cycle arrest. Therefore the fact that the 
Fox proteins can be considered as novel agents in breast 
carcinoma therapy requires further investigations (1). 
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